Sovaldi price worries states
Gilead's hepatitis C drug Sovaldi is giving Medicaid and private insurers a headache. Reuters reports that several insurers are talking with state agencies about how to handle Medicaid payments for a treatment that costs around $84,000 per person.
Reuters notes that this can also be just a starting price and that “many doctors are requesting a $150,000 combination of Sovaldi (sofosbuvir) and Olysio (simeprevir).”
This too, is a starting point of sorts: Harvard Medical School's Camilla Graham told Reuters that a cumulative number would probably hover around the $200 billion mark to treat two-thirds of hepatitis C patients at around $100,000 each.